Neues zur Genetik der Schizophrenie

Kernaussagen

• In den letzten beiden Jahren wurden große Fortschritte in der Aufklärung der Pathogenese der Schizophrenie erzielt.

• Genetische Ursachen sind vermutlich für etwa 80 % aller Schizophrenieerkrankungen verantwortlich.

• Aus der klinischen Beobachtung des häufigen Nikotinabusus bei Schizophreniepatienten ergaben sich neue Erkenntnisse zu Endophänotypen der Schizophrenie.

• Es wurden eine Reihe neuer Schizophrenierisikogene gefunden. Darüber hinaus sind große Deletionen der DNA an den Chromosomenabschnitten 1q21.1 und 15q13.3 neue pathogenetische Faktoren in der Verursachung der Schizophrenie.

• Auch sind Fortschritte in der Pharmakogenetik der Schizophrenie erzielt worden.

• Es ist zu erwarten, dass die kommenden Jahre weitere Erkenntnisse zur Rolle genetischer Befunde in der Diagnostik und Therapie schizophrener Erkrankungen bringen werden.

Publication History

Publication Date:
04 August 2010 (online)

• Literatur

• Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses.. Neurosci Biobehav Rev 2005; 29: 1021-1034
• Barr RS, Culhane MA, Jubelt LE. et al. The effects of transdermal Nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.. Neuropsychopharmacology 2008; 33: 480-490
• Zabala A, Eguiluz JI, Segarra R. et al. Cognitive performance and cigarette smoking in first-episode psychosis.. Eur Arch Psychiatry Clin Neurosci 2009; 259: 65-71
• Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.. Biochem Pharmacol 2007; 74: 1182-1191
• Graham FK. Presidential Address, 1974. The more or less startling effects of weak prestimulation.. Psychophysiology 1975; 12: 238-248
• Cadenhead KS, Swerdlow NR, Shafer KM. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits.. Am J Psychiatry 2000; 157: 1660-1668
• Quednow BB, Frommann I, Berning J. et al. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.. Biol Psychiatr 2008; 64: 766-773
• George TP, Termine A, Sacco KA. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of Nicotinic receptor mechanisms.. Schizophr Res 2006; 87: 307-315
• Hong LE, Wonodi I, Lewis J. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients.. Neuropsychopharmacology 2008; 33: 2167-2174
• Bierut LJ, Stitzel JA, Wang JC. et al. Variants in Nicotinic receptors and risk for Nicotine dependence.. Am J Psychiatry 2008; 165: 1163-1171
• Weiss RB, Baker TB, Cannon DS. et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent Nicotine addiction.. PLoS Genet 2008; 4: e1000125
• Caporaso N, Gu F, Chatterjee N. et al. Genome-wide and candidate gene association study of cigarette smoking behaviors.. PLoS One 2009; 4: e4653
• Petrovsky N. et al. Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.. Neuropsychopharmacology 2010; 35: 1429-1439
• Quednow BB, Kuhn KU, Mössner R. et al. Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms.. Biol Psychiatry 2008; 64: 434-437
• Quednow BB, Wagner M, Mössner R. et al. Sensorimotor Gating of Schizophrenia Patients Depends on Catechol O-Methyltransferase Val158Met Polymorphism.. Schizophr Bull 2010; 36: 341-346
• Roussos P, Giakoumaki SG, Bitsios P. The dopamine D(3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex.. Biol Psychiatry 2008; 64: 235-240
• O’Donovan MC, Craddock N, Norton N. et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up.. Nat Genet 2008; 40: 1053-1055
• Ruano D, Aulchenko YS, Macedo A. et al. Association of the gene encoding neurogranin with schizophrenia in males.. J Psychiatr Res 2008; 42: 125-133
• Stefansson H, Ophoff RA, Steinberg S. et al. Common variants conferring risk of schizophrenia.. Nature 2009; 460: 744-747
• de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders.. Neuropsychopharmacology 2009; 34: 159-172
• Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.. Mol Psychiatry 2007; 12: 707-747
• Mössner R, Schuhmacher A, Kuhn K. et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.. Pharmacogenet Genomics 2009; 19: 91-94
• Reynolds GP, Arranz B, Templeman LA. et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients.. Am J Psychiatry 2006; 163: 1826-1829
• Wang L, Fang C, Zhang A. et al. The –1019 C / G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.. J Psychopharmacol 2008; 22: 904-909
• Mössner R, Marshall CR, Sutcliffe JS. Contribution of SHANK3 mutations to autism spectrum disorder.. Am J Hum Genet 2007; 81: 1289-1297
• Redon R, Ishikawa S, Fitch KR. et al. Global variation in copy number in the human genome.. Nature 2006; 444: 444-454
• Marshall CR, Noor A, Vincent JB. et al. Structural variation of chromosomes in autism spectrum disorder.. Am J Hum Genet 2008; 82: 477-488
• Stefansson H, Rujescu D, Cichon S. et al. Large recurrent microdeletions associated with schizophrenia.. Nature 2008; 455: 232-236